Maravai Lifesciences Holdings, Inc. (MRVI, Financial) saw its stock price decline by 5.11%, settling at $7.89 with a trading volume of 767,277 shares and a turnover rate of 0.54%. The stock's price fluctuation reached 4.45% during the session.
The company's recent financial results revealed revenue of $73.40 million and a net loss of $7.59 million, translating to an earnings per share (EPS) of -$0.06. The gross profit stood at $28.26 million, and the price-to-earnings (P/E) ratio was -7.91. Among the 15 rating institutions, 73% recommended a buy, while 27% advised holding the stock.
Within the biotechnology sector, where Maravai Lifesciences operates, the overall increase was 0.01%. Notable performers included Cero Therapeutics Holdings Inc, Silexion Therapeutics Corp, and Lixte Biotechnology Holdings Inc, which saw significant gains. Aditxt, Inc., Silexion Therapeutics Corp, and Sagimet Biosciences Inc. were highly active with remarkable turnover rates. Significant price fluctuations were observed in Tevogen Bio Holdings Inc, Nls Pharmaceutics Ltd, and Tc Biopharm (Holdings) Plc.
Maravai Lifesciences Holdings Inc. is a life sciences company offering products that advance drug therapies, diagnostic methods, and new vaccine development. The company's segments include nucleic acid production, biologics safety testing, and protein detection. The majority of its revenue is generated from nucleic acid production catering to clients' research, therapeutic, and vaccine programs.
